Novel bone microenvironment model of castration-resistant prostate cancer with chitosan fiber matrix and osteoblasts.
bone metastasis
drug screening
osteoblast
prostate cancer
three-dimensional co-culture
Journal
Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
09
04
2021
accepted:
20
07
2021
entrez:
30
8
2021
pubmed:
31
8
2021
medline:
31
8
2021
Statut:
ppublish
Résumé
The interaction between prostate cancer cells and osteoblasts is essential for the development of bone metastasis. Previously, novel androgen receptor axis-targeted agents (ARATs) were approved for metastatic castration-naïve and non-metastatic castration-resistant prostate cancer (CRPC); both of which are pivotal for investigating the association between the bone microenvironment and tumors. The present study established a novel
Identifiants
pubmed: 34457044
doi: 10.3892/ol.2021.12950
pii: OL-0-0-12950
pmc: PMC8358738
doi:
Types de publication
Journal Article
Langues
eng
Pagination
689Informations de copyright
Copyright: © Samoto et al.
Déclaration de conflit d'intérêts
Koji Tamada holds stocks in and receives remuneration from Noile-Immune Biotech Inc., and received lecture fees from Ono Pharmaceutical, MSD, AstraZeneca, Eli Lilly Japan and Chugai Pharmaceutical. Hideyasu Matsuyama received funding from Janssen Pharmaceutical. The other authors declare that they have no competing interests.
Références
Biotechnol Bioeng. 2013 Feb;110(2):637-47
pubmed: 22991229
Adv Biosci Biotechnol. 2013 Oct 1;4(10C):15-30
pubmed: 24558636
J Clin Oncol. 2009 Apr 1;27(10):1549-56
pubmed: 19237635
J Bone Miner Res. 2014 Dec;29(12):2688-96
pubmed: 24956445
Biomacromolecules. 2015 Oct 12;16(10):3362-72
pubmed: 26347946
Cancer Res. 1983 Apr;43(4):1809-18
pubmed: 6831420
Adv Enzyme Regul. 1984;22:27-55
pubmed: 6382953
N Engl J Med. 2010 Apr 1;362(13):1192-202
pubmed: 20357281
Nature. 2016 May 25;533(7604):547-51
pubmed: 27225130
Oncotarget. 2017 May 23;8(21):35376-35389
pubmed: 28430640
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Biomaterials. 2019 Oct;217:119311
pubmed: 31279100
Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6213s-6216s
pubmed: 17062703
Lancet Oncol. 2015 Feb;16(2):152-60
pubmed: 25601341
Oncotarget. 2016 Sep 27;7(39):64447-64470
pubmed: 27487144
J Biomed Mater Res A. 2017 Aug;105(8):2119-2128
pubmed: 28371246
Int J Nanomedicine. 2014 Sep 09;9:4293-304
pubmed: 25246786
Bone. 2011 Jan;48(1):23-9
pubmed: 20699127
Cold Spring Harb Perspect Med. 2018 Jun 1;8(6):
pubmed: 29101113
Cancers (Basel). 2020 Mar 25;12(4):
pubmed: 32218271
Nat Commun. 2018 Jul 30;9(1):2981
pubmed: 30061695
N Engl J Med. 2016 Oct 13;375(15):1415-1424
pubmed: 27626136
J Steroid Biochem Mol Biol. 2017 Feb;166:84-90
pubmed: 27189666
Cancer Res. 2011 Oct 15;71(20):6503-13
pubmed: 21868758
Clin Cancer Res. 2003 Jul;9(7):2587-97
pubmed: 12855635
N Engl J Med. 2015 Aug 20;373(8):737-46
pubmed: 26244877
Br J Cancer. 2011 Feb 1;104(3):505-13
pubmed: 21206493
Sci Rep. 2017 Mar 17;7:44824
pubmed: 28303941
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Mol Cancer Ther. 2007 Oct;6(10):2609-17
pubmed: 17938257
Nat Rev Cancer. 2011 Jun;11(6):411-25
pubmed: 21593787
Endocr Relat Cancer. 2015 Dec;22(6):889-900
pubmed: 26311513
Biomaterials. 2020 Sep;254:120126
pubmed: 32480094
Nat Rev Cancer. 2013 Nov;13(11):788-99
pubmed: 24132110
Nature. 2013 Sep 19;501(7467):365-72
pubmed: 24048069
Eur Urol. 2014 Feb;65(2):270-273
pubmed: 24295792
Front Cell Dev Biol. 2016 Jun 23;4:64
pubmed: 27446916
Acta Biomater. 2019 Aug;94:392-409
pubmed: 31200118